A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | MicrobiomeTrials← Back to trialsNCT06375993
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
ENROLLING_BY_INVITATIONPHASE1INTERVENTIONAL
Trial Details
Start: 2024-11-10Est. Completion: 2026-12
Enrollment target: 180 participants Locations- Adicet Clinical Trials, Redwood City, California, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Other microbiome trials you might be interested in
Lupus Erythematosus, Systemic
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell thera…
San Francisco, United StatesEst. completion May 1, 2029
Systemic Lupus Erythematosus (SLE)
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic…
Phoenix, United StatesCompleted Mar 29, 2030
Phase 1
Recruiting
This study is researching a particular group of experimental drugs administered for a short period in the treatment of p…
Rochester, United StatesEst. completion Sep 9, 2029